Mostrar el registro sencillo del ítem
dc.contributor.author | Galiana, Irene | es_ES |
dc.contributor.author | Lozano-Torres, Beatriz | es_ES |
dc.contributor.author | Sancho, Mónica | es_ES |
dc.contributor.author | Alfonso-Navarro, María | es_ES |
dc.contributor.author | Bernardos Bau, Andrea | es_ES |
dc.contributor.author | Bisbal, Viviana | es_ES |
dc.contributor.author | Serrano, Manuel | es_ES |
dc.contributor.author | Martínez-Máñez, Ramón | es_ES |
dc.contributor.author | Orzaez, Mar | es_ES |
dc.date.accessioned | 2021-02-16T04:32:59Z | |
dc.date.available | 2021-02-16T04:32:59Z | |
dc.date.issued | 2020-07 | es_ES |
dc.identifier.issn | 0168-3659 | es_ES |
dc.identifier.uri | http://hdl.handle.net/10251/161402 | |
dc.description.abstract | [EN] The induction of senescence produces a stable cell cycle arrest in cancer cells, thereby inhibiting tumor growth; however, the incomplete immune cell-mediated clearance of senescent cells may favor tumor relapse, limiting the long-term anti-tumorigenic effect of such drugs. A combination of senescence induction and the elimination of senescent cells may, therefore, represent an efficient means to inhibit tumor relapse. In this study, we explored the antitumor efficacy of a combinatory senogenic and targeted senolytic therapy in an immunocompetent orthotopic mouse model of the aggressive triple negative breast cancer subtype. Following palbociclib-induced senogenesis and senolysis by treatment with nano-encapsulated senolytic agent navitoclax, we observed inhibited tumor growth, reduced metastases, and a reduction in the systemic toxicity of navitoclax. We believe that this combination treatment approach may have relevance to other senescence-inducing chemotherapeutic drugs and additional tumor types. Significance: While the application of senescence inducers represents a successful treatment strategy in breast cancer patients, some patients still relapse, perhaps due to the subsequent accumulation of senescent cells in the body that can promote tumor recurrence. We now demonstrate that a combination treatment of a senescence inducer and a senolytic nanoparticle selectively eliminates senescent cells, delays tumor growth, and reduces metastases in a mouse model of aggressive breast cancer. Collectively, our results support targeted senolysis as a new therapeutic opportunity to improve outcomes in breast cancer patients. | es_ES |
dc.description.sponsorship | The M.O. laboratory members thank the financial support from the Spanish Government (project SAF2017-84689-R (MINECO/AEI/FEDER, EU)) and the Generalitat Valenciana (project PROMETEO/2019/065). The R.M. laboratory members thank the financial support from the Spanish Government (projects RTI2018-100910-B-C41 and RTI2018-101599-B-C22 (MCUI/FEDER, EU) and the Generalitat Valenciana (project PROMETEO 2018/024). Both I.G. and B.L-T. are grateful to the Generalitat Valenciana and the Spanish Ministry of Economy, respectively, for their Ph.D. grants. I.G. would like to thank I. Borreda and J. Forteza and the Instituto Valenciano de Patologia for their special collaboration and F. Sancenon for his appreciated help | es_ES |
dc.language | Inglés | es_ES |
dc.publisher | Elsevier | es_ES |
dc.relation.ispartof | Journal of Controlled Release | es_ES |
dc.rights | Reserva de todos los derechos | es_ES |
dc.subject | Breast Cancer | es_ES |
dc.subject | Mesoporous silica nanoparticles | es_ES |
dc.subject | Senescence | es_ES |
dc.subject | Senolysis | es_ES |
dc.subject.classification | QUIMICA INORGANICA | es_ES |
dc.subject.classification | QUIMICA ORGANICA | es_ES |
dc.subject.classification | QUIMICA ANALITICA | es_ES |
dc.subject.classification | BIOQUIMICA Y BIOLOGIA MOLECULAR | es_ES |
dc.title | Preclinical antitumor efficacy of senescence-inducing chemotherapy combined with a nanoSenolytic | es_ES |
dc.type | Artículo | es_ES |
dc.identifier.doi | 10.1016/j.jconrel.2020.04.045 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/SAF2017-84689-R/ES/DESCIFRANDO Y MODULANDO EL INTERACTOMA TRANSMEMBRANA DE LAS PROTEINAS BCL-2 COMO DIANA ANTITUMORAL/ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/RTI2018-101599-B-C22/ES/DESARROLLO Y APLICACION DE SISTEMAS ANTIMICROBIANOS PARA LA INDUSTRIA ALIMENTARIA BASADOS EN SUPERFICIES FUNCIONALIZADAS Y SISTEMAS DE LIBERACION CONTROLADA/ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/GVA//PROMETEO%2F2019%2F065/ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/GVA//PROMETEO%2F2018%2F024/ES/Sistemas avanzados de liberación controlada/ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/RTI2018-100910-B-C41/ES/MATERIALES POROSOS INTELIGENTES MULTIFUNCIONALES Y DISPOSITIVOS ELECTRONICOS PARA LA LIBERACION DE FARMACOS, DETECCION DE DROGAS Y BIOMARCADORES Y COMUNICACION A NANOESCALA/ | es_ES |
dc.rights.accessRights | Abierto | es_ES |
dc.contributor.affiliation | Universitat Politècnica de València. Departamento de Química - Departament de Química | es_ES |
dc.description.bibliographicCitation | Galiana, I.; Lozano-Torres, B.; Sancho, M.; Alfonso-Navarro, M.; Bernardos Bau, A.; Bisbal, V.; Serrano, M.... (2020). Preclinical antitumor efficacy of senescence-inducing chemotherapy combined with a nanoSenolytic. Journal of Controlled Release. 323:624-634. https://doi.org/10.1016/j.jconrel.2020.04.045 | es_ES |
dc.description.accrualMethod | S | es_ES |
dc.relation.publisherversion | https://doi.org/10.1016/j.jconrel.2020.04.045 | es_ES |
dc.description.upvformatpinicio | 624 | es_ES |
dc.description.upvformatpfin | 634 | es_ES |
dc.type.version | info:eu-repo/semantics/publishedVersion | es_ES |
dc.description.volume | 323 | es_ES |
dc.identifier.pmid | 32376460 | es_ES |
dc.relation.pasarela | S\395072 | es_ES |
dc.contributor.funder | Generalitat Valenciana | es_ES |
dc.contributor.funder | Agencia Estatal de Investigación | es_ES |
dc.contributor.funder | European Regional Development Fund | es_ES |
dc.description.references | Hernandez-Segura, A., Nehme, J., & Demaria, M. (2018). Hallmarks of Cellular Senescence. Trends in Cell Biology, 28(6), 436-453. doi:10.1016/j.tcb.2018.02.001 | es_ES |
dc.description.references | Acosta, J. C., & Gil, J. (2012). Senescence: a new weapon for cancer therapy. Trends in Cell Biology, 22(4), 211-219. doi:10.1016/j.tcb.2011.11.006 | es_ES |
dc.description.references | Sieben, C. J., Sturmlechner, I., van de Sluis, B., & van Deursen, J. M. (2018). Two-Step Senescence-Focused Cancer Therapies. Trends in Cell Biology, 28(9), 723-737. doi:10.1016/j.tcb.2018.04.006 | es_ES |
dc.description.references | Goldman, J. W., Shi, P., Reck, M., Paz-Ares, L., Koustenis, A., & Hurt, K. C. (2016). Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non–Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy. Clinical Lung Cancer, 17(1), 80-84. doi:10.1016/j.cllc.2015.08.003 | es_ES |
dc.description.references | Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., … Slamon, D. J. (2009). PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Research, 11(5). doi:10.1186/bcr2419 | es_ES |
dc.description.references | Geoerger, B., Bourdeaut, F., DuBois, S. G., Fischer, M., Geller, J. I., Gottardo, N. G., … Chi, S. N. (2017). A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors. Clinical Cancer Research, 23(10), 2433-2441. doi:10.1158/1078-0432.ccr-16-2898 | es_ES |
dc.description.references | Kwapisz, D. (2017). Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib. Breast Cancer Research and Treatment, 166(1), 41-54. doi:10.1007/s10549-017-4385-3 | es_ES |
dc.description.references | Pernas, S., Tolaney, S. M., Winer, E. P., & Goel, S. (2018). CDK4/6 inhibition in breast cancer: current practice and future directions. Therapeutic Advances in Medical Oncology, 10, 175883591878645. doi:10.1177/1758835918786451 | es_ES |
dc.description.references | Sutherland, R. L., & Musgrove, E. A. (2009). CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+disease. Breast Cancer Research, 11(6). doi:10.1186/bcr2454 | es_ES |
dc.description.references | Beaver, J. A., Amiri-Kordestani, L., Charlab, R., Chen, W., Palmby, T., Tilley, A., … Cortazar, P. (2015). FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer. Clinical Cancer Research, 21(21), 4760-4766. doi:10.1158/1078-0432.ccr-15-1185 | es_ES |
dc.description.references | Chiu, J. W., Kwok, G., Yau, T., & Leung, R. (2017). Editorial to «Palbociclib and letrozole in advanced breast cancer». Translational Cancer Research, 6(S2), S376-S379. doi:10.21037/tcr.2017.03.21 | es_ES |
dc.description.references | Traina, T., Cadoo, K., & Gucalp, A. (2014). Palbociclib: an evidence-based review of its potential in the treatment of breast cancer. Breast Cancer: Targets and Therapy, 123. doi:10.2147/bctt.s46725 | es_ES |
dc.description.references | Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., … Cristofanilli, M. (2015). Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer. New England Journal of Medicine, 373(3), 209-219. doi:10.1056/nejmoa1505270 | es_ES |
dc.description.references | Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., … Slamon, D. (2016). Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. The Lancet Oncology, 17(4), 425-439. doi:10.1016/s1470-2045(15)00613-0 | es_ES |
dc.description.references | Lee, S., & Schmitt, C. A. (2019). The dynamic nature of senescence in cancer. Nature Cell Biology, 21(1), 94-101. doi:10.1038/s41556-018-0249-2 | es_ES |
dc.description.references | Giaimo, S., & d’ Adda di Fagagna, F. (2012). Is cellular senescence an example of antagonistic pleiotropy? Aging Cell, 11(3), 378-383. doi:10.1111/j.1474-9726.2012.00807.x | es_ES |
dc.description.references | Muñoz-Espín, D., & Serrano, M. (2014). Cellular senescence: from physiology to pathology. Nature Reviews Molecular Cell Biology, 15(7), 482-496. doi:10.1038/nrm3823 | es_ES |
dc.description.references | Rodier, F., & Campisi, J. (2011). Four faces of cellular senescence. Journal of Cell Biology, 192(4), 547-556. doi:10.1083/jcb.201009094 | es_ES |
dc.description.references | He, S., & Sharpless, N. E. (2017). Senescence in Health and Disease. Cell, 169(6), 1000-1011. doi:10.1016/j.cell.2017.05.015 | es_ES |
dc.description.references | McHugh, D., & Gil, J. (2017). Senescence and aging: Causes, consequences, and therapeutic avenues. Journal of Cell Biology, 217(1), 65-77. doi:10.1083/jcb.201708092 | es_ES |
dc.description.references | Ewald, J. A., Desotelle, J. A., Wilding, G., & Jarrard, D. F. (2010). Therapy-Induced Senescence in Cancer. JNCI: Journal of the National Cancer Institute, 102(20), 1536-1546. doi:10.1093/jnci/djq364 | es_ES |
dc.description.references | Gordon, R. R., & Nelson, P. S. (2012). Cellular senescence and cancer chemotherapy resistance. Drug Resistance Updates, 15(1-2), 123-131. doi:10.1016/j.drup.2012.01.002 | es_ES |
dc.description.references | Wieland, E., Rodriguez-Vita, J., Liebler, S. S., Mogler, C., Moll, I., Herberich, S. E., … Fischer, A. (2017). Endothelial Notch1 Activity Facilitates Metastasis. Cancer Cell, 31(3), 355-367. doi:10.1016/j.ccell.2017.01.007 | es_ES |
dc.description.references | Milanovic, M., Fan, D. N. Y., Belenki, D., Däbritz, J. H. M., Zhao, Z., Yu, Y., … Schmitt, C. A. (2017). Senescence-associated reprogramming promotes cancer stemness. Nature, 553(7686), 96-100. doi:10.1038/nature25167 | es_ES |
dc.description.references | Parrinello, S., Coppe, J.-P., Krtolica, A., & Campisi, J. (2005). Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation. Journal of Cell Science, 118(3), 485-496. doi:10.1242/jcs.01635 | es_ES |
dc.description.references | Kirkland, J. L., Tchkonia, T., Zhu, Y., Niedernhofer, L. J., & Robbins, P. D. (2017). The Clinical Potential of Senolytic Drugs. Journal of the American Geriatrics Society, 65(10), 2297-2301. doi:10.1111/jgs.14969 | es_ES |
dc.description.references | Childs, B. G., Gluscevic, M., Baker, D. J., Laberge, R.-M., Marquess, D., Dananberg, J., & van Deursen, J. M. (2017). Senescent cells: an emerging target for diseases of ageing. Nature Reviews Drug Discovery, 16(10), 718-735. doi:10.1038/nrd.2017.116 | es_ES |
dc.description.references | Lozano-Torres, B., Estepa-Fernández, A., Rovira, M., Orzáez, M., Serrano, M., Martínez-Máñez, R., & Sancenón, F. (2019). The chemistry of senescence. Nature Reviews Chemistry, 3(7), 426-441. doi:10.1038/s41570-019-0108-0 | es_ES |
dc.description.references | Zhu, Y., Tchkonia, T., Fuhrmann‐Stroissnigg, H., Dai, H. M., Ling, Y. Y., Stout, M. B., … Kirkland, J. L. (2016). Identification of a novel senolytic agent, navitoclax, targeting the Bcl‐2 family of anti‐apoptotic factors. Aging Cell, 15(3), 428-435. doi:10.1111/acel.12445 | es_ES |
dc.description.references | Baar, M. P., Brandt, R. M. C., Putavet, D. A., Klein, J. D. D., Derks, K. W. J., Bourgeois, B. R. M., … de Keizer, P. L. J. (2017). Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell, 169(1), 132-147.e16. doi:10.1016/j.cell.2017.02.031 | es_ES |
dc.description.references | Zhu, Y., Tchkonia, T., Pirtskhalava, T., Gower, A. C., Ding, H., Giorgadze, N., … Kirkland, J. L. (2015). The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell, 14(4), 644-658. doi:10.1111/acel.12344 | es_ES |
dc.description.references | Chang, J., Wang, Y., Shao, L., Laberge, R.-M., Demaria, M., Campisi, J., … Zhou, D. (2015). Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nature Medicine, 22(1), 78-83. doi:10.1038/nm.4010 | es_ES |
dc.description.references | Kile, B. T. (2014). The role of apoptosis in megakaryocytes and platelets. British Journal of Haematology, 165(2), 217-226. doi:10.1111/bjh.12757 | es_ES |
dc.description.references | Aznar, E., Oroval, M., Pascual, L., Murguía, J. R., Martínez-Máñez, R., & Sancenón, F. (2016). Gated Materials for On-Command Release of Guest Molecules. Chemical Reviews, 116(2), 561-718. doi:10.1021/acs.chemrev.5b00456 | es_ES |
dc.description.references | Llopis-Lorente, A., Lozano-Torres, B., Bernardos, A., Martínez-Máñez, R., & Sancenón, F. (2017). Mesoporous silica materials for controlled delivery based on enzymes. Journal of Materials Chemistry B, 5(17), 3069-3083. doi:10.1039/c7tb00348j | es_ES |
dc.description.references | Su, Y.-L., & Hu, S.-H. (2018). Functional Nanoparticles for Tumor Penetration of Therapeutics. Pharmaceutics, 10(4), 193. doi:10.3390/pharmaceutics10040193 | es_ES |
dc.description.references | Giménez, C., de la Torre, C., Gorbe, M., Aznar, E., Sancenón, F., Murguía, J. R., … Amorós, P. (2015). Gated Mesoporous Silica Nanoparticles for the Controlled Delivery of Drugs in Cancer Cells. Langmuir, 31(12), 3753-3762. doi:10.1021/acs.langmuir.5b00139 | es_ES |
dc.description.references | Agostini, A., Mondragón, L., Bernardos, A., Martínez-Máñez, R., Marcos, M. D., Sancenón, F., … Murguía, J. R. (2012). Targeted Cargo Delivery in Senescent Cells Using Capped Mesoporous Silica Nanoparticles. Angewandte Chemie International Edition, 51(42), 10556-10560. doi:10.1002/anie.201204663 | es_ES |
dc.description.references | Bernardos, A., Mondragón, L., Aznar, E., Marcos, M. D., Martínez-Máñez, R., Sancenón, F., … Amorós, P. (2010). Enzyme-Responsive Intracellular Controlled Release Using Nanometric Silica Mesoporous Supports Capped with «Saccharides». ACS Nano, 4(11), 6353-6368. doi:10.1021/nn101499d | es_ES |
dc.description.references | Kaur, P., Nagaraja, G. M., Zheng, H., Gizachew, D., Galukande, M., Krishnan, S., & Asea, A. (2012). A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease. BMC Cancer, 12(1). doi:10.1186/1471-2407-12-120 | es_ES |
dc.description.references | Foulkes, W. D., Smith, I. E., & Reis-Filho, J. S. (2010). Triple-Negative Breast Cancer. New England Journal of Medicine, 363(20), 1938-1948. doi:10.1056/nejmra1001389 | es_ES |
dc.description.references | Collado, M., & Serrano, M. (2010). Senescence in tumours: evidence from mice and humans. Nature Reviews Cancer, 10(1), 51-57. doi:10.1038/nrc2772 | es_ES |
dc.description.references | Goel, S., DeCristo, M. J., Watt, A. C., BrinJones, H., Sceneay, J., Li, B. B., … Zhao, J. J. (2017). CDK4/6 inhibition triggers anti-tumour immunity. Nature, 548(7668), 471-475. doi:10.1038/nature23465 | es_ES |
dc.description.references | Asghar, U. S., Barr, A. R., Cutts, R., Beaney, M., Babina, I., Sampath, D., … Turner, N. C. (2017). Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer. Clinical Cancer Research, 23(18), 5561-5572. doi:10.1158/1078-0432.ccr-17-0369 | es_ES |
dc.description.references | Lee, B. Y., Han, J. A., Im, J. S., Morrone, A., Johung, K., Goodwin, E. C., … Hwang, E. S. (2006). Senescence-associated β-galactosidase is lysosomal β-galactosidase. Aging Cell, 5(2), 187-195. doi:10.1111/j.1474-9726.2006.00199.x | es_ES |
dc.description.references | Potter, D. S., & Letai, A. (2016). To Prime, or Not to Prime: That Is the Question. Cold Spring Harbor Symposia on Quantitative Biology, 81, 131-140. doi:10.1101/sqb.2016.81.030841 | es_ES |
dc.description.references | Billard, C. (2013). BH3 Mimetics: Status of the Field and New Developments. Molecular Cancer Therapeutics, 12(9), 1691-1700. doi:10.1158/1535-7163.mct-13-0058 | es_ES |
dc.description.references | Reers, M., Smiley, S. T., Mottola-Hartshorn, C., Chen, A., Lin, M., & Chen, L. B. (1995). [29] Mitochondrial membrane potential monitored by JC-1 dye. Mitochondrial Biogenesis and Genetics Part A, 406-417. doi:10.1016/0076-6879(95)60154-6 | es_ES |
dc.description.references | Sugrue, M. M., Wang, Y., Rideout, H. J., Chalmers-Redman, R. M. E., & Tatton, W. G. (1999). Reduced Mitochondrial Membrane Potential and Altered Responsiveness of a Mitochondrial Membrane Megachannel in p53-Induced Senescence. Biochemical and Biophysical Research Communications, 261(1), 123-130. doi:10.1006/bbrc.1999.0984 | es_ES |
dc.description.references | Wang, D., Liu, Y., Zhang, R., Zhang, F., Sui, W., Chen, L., … Ji, J. (2016). Apoptotic transition of senescent cells accompanied with mitochondrial hyper-function. Oncotarget, 7(19), 28286-28300. doi:10.18632/oncotarget.8536 | es_ES |
dc.description.references | Collado, M., Gil, J., Efeyan, A., Guerra, C., Schuhmacher, A. J., Barradas, M., … Serrano, M. (2005). Senescence in premalignant tumours. Nature, 436(7051), 642-642. doi:10.1038/436642a | es_ES |
dc.description.references | Baker, D. J., Wijshake, T., Tchkonia, T., LeBrasseur, N. K., Childs, B. G., van de Sluis, B., … van Deursen, J. M. (2011). Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature, 479(7372), 232-236. doi:10.1038/nature10600 | es_ES |
dc.description.references | Jaskelioff, M., Muller, F. L., Paik, J.-H., Thomas, E., Jiang, S., Adams, A. C., … DePinho, R. A. (2010). Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice. Nature, 469(7328), 102-106. doi:10.1038/nature09603 | es_ES |
dc.description.references | Lehmann, M., Korfei, M., Mutze, K., Klee, S., Skronska-Wasek, W., Alsafadi, H. N., … Königshoff, M. (2017). Senolytic drugs target alveolar epithelial cell function and attenuate experimental lung fibrosisex vivo. European Respiratory Journal, 50(2), 1602367. doi:10.1183/13993003.02367-2016 | es_ES |
dc.description.references | Schafer, M. J., White, T. A., Iijima, K., Haak, A. J., Ligresti, G., Atkinson, E. J., … LeBrasseur, N. K. (2017). Cellular senescence mediates fibrotic pulmonary disease. Nature Communications, 8(1). doi:10.1038/ncomms14532 | es_ES |
dc.description.references | Hecker, L., Logsdon, N. J., Kurundkar, D., Kurundkar, A., Bernard, K., Hock, T., … Thannickal, V. J. (2014). Reversal of Persistent Fibrosis in Aging by Targeting Nox4-Nrf2 Redox Imbalance. Science Translational Medicine, 6(231). doi:10.1126/scitranslmed.3008182 | es_ES |
dc.description.references | Sanders, Y. Y., Liu, H., Liu, G., & Thannickal, V. J. (2015). Epigenetic mechanisms regulate NADPH oxidase-4 expression in cellular senescence. Free Radical Biology and Medicine, 79, 197-205. doi:10.1016/j.freeradbiomed.2014.12.008 | es_ES |
dc.description.references | Soto-Gamez, A., & Demaria, M. (2017). Therapeutic interventions for aging: the case of cellular senescence. Drug Discovery Today, 22(5), 786-795. doi:10.1016/j.drudis.2017.01.004 | es_ES |
dc.description.references | Burd, C. E., Sorrentino, J. A., Clark, K. S., Darr, D. B., Krishnamurthy, J., Deal, A. M., … Sharpless, N. E. (2013). Monitoring Tumorigenesis and Senescence In Vivo with a p16INK4a-Luciferase Model. Cell, 152(1-2), 340-351. doi:10.1016/j.cell.2012.12.010 | es_ES |
dc.description.references | Correia-Melo, C., & Passos, J. F. (2015). Mitochondria: Are they causal players in cellular senescence? Biochimica et Biophysica Acta (BBA) - Bioenergetics, 1847(11), 1373-1379. doi:10.1016/j.bbabio.2015.05.017 | es_ES |